Search Results - "Princen, H. M. G."

APOE3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome by van den Hoek, A. M., van der Hoorn, J. W. A., Maas, A. C., van den Hoogen, R. M., van Nieuwkoop, A., Droog, S., Offerman, E. H., Pieterman, E. J., Havekes, L. M., Princen, H. M. G.

“…Aims This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl…”
Get full text

Accelerated Atherosclerosis by Placement of a Perivascular Cuff and a Cholesterol-Rich Diet in ApoE3Leiden Transgenic Mice by Lardenoye, J H. P, Delsing, D J. M, de Vries, M R, Deckers, M M. L, Princen, H M. G, Havekes, L M, van Hinsbergh, V W. M, van Bockel, J H, Quax, P H. A

“…Intimal hyperplasia after vascular injury is usually studied in animal models with healthy, normocholesterolemic animals. Here, we assess the effect of…”
Get full text

IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model by van Gemert, Y., Kruisbergen, N.N.L., Blom, A.B., van den Bosch, M.H.J., van der Kraan, P.M., Pieterman, E.J., Princen, H.M.G., van Lent, P.L.E.M.

“…Both systemic inflammation and dyslipidemia contribute to osteoarthritis (OA) development and have been suggested as a possible link between metabolic disease…”
Get full text

Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice by van Gemert, Y., Kozijn, A.E., Pouwer, M.G., Kruisbergen, N.N.L., van den Bosch, M.H.J., Blom, A.B., Pieterman, E.J., Weinans, H., Stoop, R., Princen, H.M.G., van Lent, P.L.E.M.

“…High systemic cholesterol levels have been associated with osteoarthritis (OA) development. Therefore, cholesterol lowering by statins has been suggested as a…”
Get full text

Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice by van Gemert, Y., Blom, A.B., Di Ceglie, I., Walgreen, B., Helsen, M., Sloetjes, A., Vogl, T., Roth, J., Kruisbergen, N.N.L., Pieterman, E.J., Princen, H.M.G., van der Kraan, P.M., van Lent, P.L.E.M., van den Bosch, M.H.J.

“…The association between metabolic syndrome (MetS) and osteoarthritis (OA) development has become increasingly recognized. In this context, the exact role of…”
Get full text

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin by Kühnast, Susan, van der Tuin, Sam J L, van der Hoorn, José W A, van Klinken, Jan B, Simic, Branko, Pieterman, Elsbet, Havekes, Louis M, Landmesser, Ulf, Lüscher, Thomas F, Willems van Dijk, Ko, Rensen, Patrick C N, Jukema, J Wouter, Princen, Hans M G

“…The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary…”
Get full text

Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought by Kozijn, A.E., Gierman, L.M., van der Ham, F., Mulder, P., Morrison, M.C., Kühnast, S., van der Heijden, R.A., Stavro, P.M., van Koppen, A., Pieterman, E.J., van den Hoek, A.M., Kleemann, R., Princen, H.M.G., Mastbergen, S.C., Lafeber, F.P.J.G., Zuurmond, A.-M., Bobeldijk, I., Weinans, H., Stoop, R.

“…Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the…”
Get full text

Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss by Kockx, M, Leenen, R, Seidell, J, Princen, H M, Kooistra, T

“…This study was aimed at evaluating the relationship between visceral fat accumulation and plasma plasminogen activator inhibitor-1 (PAI-1) levels in healthy,…”
Get more information

Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes by NEELE, D. M, DE WIT, E. C. M, PRINCEN, H. M. G

“…Raised plasma lipoprotein(a) (lp(a)) concentrations have been reported in patients with Type I (insulin-dependent) diabetes mellitus, which were lowered by…”
Get full text

Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE3Leiden mice without affecting liver or plasma triglyceride levels by van der Hoorn, JWA, Lindén, D, Lindahl, U, Bekkers, MEA, Voskuilen, M, Nilsson, R, Oscarsson, J, Lindstedt, EL, Princen, HMG

“…BACKGROUND AND PURPOSE Liver X receptor (LXR) agonists are atheroprotective but often induce hypertriglyceridaemia and liver steatosis. We investigated the…”
Get full text

Fenofibrate Reduces Atherogenesis in ApoE3Leiden Mice: Evidence for Multiple Antiatherogenic Effects Besides Lowering Plasma Cholesterol by Kooistra, T, Verschuren, L, de Vries-van der Weij, J, Koenig, W, Toet, K, Princen, H M.G, Kleemann, R

“…OBJECTIVE—To demonstrate, quantify, and mechanistically dissect antiatherosclerotic effects of fenofibrate besides lowering plasma cholesterol per se. METHODS…”
Get full text

Safety of long-term consumption of plant sterol esters-enriched spread by HENDRIKS, H. F. J, BRINK, E. J, MEIJER, G. W, PRINCEN, H. M. G, NTANIOS, F. Y

“…To evaluate both efficacy and safety in humans of long-term consumption of spreads containing plant sterol esters. Randomized double-blind placebo-controlled…”
Get full text

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus by van de Ree, M.A, Huisman, M.V, Princen, H.M.G, Meinders, A.E, Kluft, C

“…Objective: Statins are known to reduce CRP concentrations, but whether high doses are more effective is not known. Methods: In a prospective double-blind…”
Get full text

No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E3-Leiden/Human C-Reactive Protein Transgenic Mice by Trion, A, de Maat, M P.M, Jukema, J W, van der Laarse, A, Maas, M C, Offerman, E H, Havekes, L M, Szalai, A J, Princen, H M.G, Emeis, J J

“…OBJECTIVE—C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development…”
Get full text

The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE3Leiden.CETP transgenic mice by Van Der Hoorn, JWA, Jukema, JW, Havekes, LM, Lundholm, E, Camejo, G, Rensen, PCN, Princen, HMG

“…Background and purpose:  We have evaluated the effects of a peroxisome proliferator‐activated receptor (PPAR)α/γ agonist on the progression of pre‐existing…”
Get full text

Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes by Kooistra, T, Bosma, P J, Töns, H A, van den Berg, A P, Meyer, P, Princen, H M

“…Clinical studies have shown that plasma insulin levels are closely related to plasma plasminogen activator inhibitor 1 (PAI-1) levels. To investigate a…”
Get more information

Consumption of black and green tea has no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals by DE MAAT, M. P. M, PIJL, H, KLUFT, C, PRINCEN, H. M. G

“…Objective: Firstly, to study the effect of tea and tea polyphenols on cardiovascular risk indicators of the inflammatory system (IL6, IL1β and TNF-α, CRP), and…”
Get full text

Modulating effect of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individuals by HOFMAN, M. K, GROENENDIJK, M, VERKUIJLEN, Pjjh, JONKERS, Ijam, MOHRSCHLADT, M. F, SMELT, A. H. M, PRINCEN, H. M. G

“…The rate-limiting enzyme in the conversion of cholesterol into bile acids is cholesterol 7alpha-hydroxylase (CYP7A1). An A to C substitution 278 bp upstream in…”
Get full text

Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus by Van De Ree, M. A., De Maat, M. P. M., Kluft, C., Meinders, A. E., Princen, H. M. G., Huisman, M. V.

“…Background: Patients with Type 2 diabetes mellitus have increased levels of hemostatic risk variables for cardiovascular disease, such as fibrinogen, von…”
Get full text

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease by Dewey, Frederick E, Gusarova, Viktoria, Dunbar, Richard L, O’Dushlaine, Colm, Schurmann, Claudia, Gottesman, Omri, McCarthy, Shane, Van Hout, Cristopher V, Bruse, Shannon, Dansky, Hayes M, Leader, Joseph B, Murray, Michael F, Ritchie, Marylyn D, Kirchner, H. Lester, Habegger, Lukas, Lopez, Alex, Penn, John, Zhao, An, Shao, Weiping, Stahl, Neil, Murphy, Andrew J, Hamon, Sara, Bouzelmat, Aurelie, Zhang, Rick, Shumel, Brad, Pordy, Robert, Gipe, Daniel, Herman, Gary A, Sheu, Wayne H.H, Lee, I-Te, Liang, Kae-Woei, Guo, Xiuqing, Rotter, Jerome I, Chen, Yii-Der I, Kraus, William E, Shah, Svati H, Damrauer, Scott, Small, Aeron, Rader, Daniel J, Wulff, Anders Berg, Nordestgaard, Børge G, Tybjærg-Hansen, Anne, van den Hoek, Anita M, Princen, Hans M.G, Ledbetter, David H, Carey, David J, Overton, John D, Reid, Jeffrey G, Sasiela, William J, Banerjee, Poulabi, Shuldiner, Alan R, Borecki, Ingrid B, Teslovich, Tanya M, Yancopoulos, George D, Mellis, Scott J, Gromada, Jesper, Baras, Aris

“…Loss-of-function variants in ANGPTL3 were associated with lower plasma levels of lipids and lower rates of coronary disease. A monoclonal antibody against…”
Get full text